tirzepatide surmount 2 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity SURMOUNT-1 Trial - Cardionerds Twitter

PMID: 19249625

If adverse effects are the primary concern, dose adjustment or symptomatic management strategies might allow continuation

In the TRIUMPH-4 trial , published by Eli Lilly in December 2025, participants taking the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks , and WOMAC pain scores were reduced significantly

The injectable method for weight loss is championed by various celebrities, such as Kelly Clarkson, Oprah Winfrey, Rebel Wilson, Tracy Morgan, and more, for its role in promoting weight loss and improving metabolic health

Corrections were made for liquid junction potentials in the experiments to measure the Cl dependency of glycine and GABA-induced currents, as calculated by the program JPCalc within the pCLAMP software